1. Home
  2. ZLAB vs SKT Comparison

ZLAB vs SKT Comparison

Compare ZLAB & SKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • SKT
  • Stock Information
  • Founded
  • ZLAB 2013
  • SKT 1981
  • Country
  • ZLAB China
  • SKT United States
  • Employees
  • ZLAB N/A
  • SKT N/A
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • SKT Real Estate Investment Trusts
  • Sector
  • ZLAB Health Care
  • SKT Real Estate
  • Exchange
  • ZLAB Nasdaq
  • SKT Nasdaq
  • Market Cap
  • ZLAB 3.5B
  • SKT 3.4B
  • IPO Year
  • ZLAB 2017
  • SKT 1993
  • Fundamental
  • Price
  • ZLAB $29.24
  • SKT $30.18
  • Analyst Decision
  • ZLAB Buy
  • SKT Buy
  • Analyst Count
  • ZLAB 4
  • SKT 9
  • Target Price
  • ZLAB $47.37
  • SKT $36.00
  • AVG Volume (30 Days)
  • ZLAB 1.2M
  • SKT 1.2M
  • Earning Date
  • ZLAB 05-08-2025
  • SKT 04-30-2025
  • Dividend Yield
  • ZLAB N/A
  • SKT 3.88%
  • EPS Growth
  • ZLAB N/A
  • SKT N/A
  • EPS
  • ZLAB N/A
  • SKT 0.85
  • Revenue
  • ZLAB $418,326,000.00
  • SKT $549,227,000.00
  • Revenue This Year
  • ZLAB $44.43
  • SKT $0.30
  • Revenue Next Year
  • ZLAB $48.68
  • SKT $4.14
  • P/E Ratio
  • ZLAB N/A
  • SKT $35.57
  • Revenue Growth
  • ZLAB 43.72
  • SKT 12.63
  • 52 Week Low
  • ZLAB $15.65
  • SKT $25.94
  • 52 Week High
  • ZLAB $39.77
  • SKT $37.57
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 42.71
  • SKT 42.18
  • Support Level
  • ZLAB $27.61
  • SKT $29.11
  • Resistance Level
  • ZLAB $32.02
  • SKT $32.42
  • Average True Range (ATR)
  • ZLAB 1.23
  • SKT 0.85
  • MACD
  • ZLAB -0.18
  • SKT -0.10
  • Stochastic Oscillator
  • ZLAB 23.41
  • SKT 27.16

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

About SKT Tanger Inc.

Tanger Inc is an owners and operators of outlet and open-air centers in the United States and Canada. It is a fully-integrated, self-administered and self-managed REIT, which focuses on developing, acquiring, owning, operating and managing outlet and open-air shopping centers. Its consolidated portfolio consisted of 31 outlet centers and 2 open-air lifestyle centers, with a total gross leasable area of approximately 13.0 million square feet.

Share on Social Networks: